An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC

Familial Cancer

Volumn 9, Issue 2, 2010, Pages 141-150

  Goldberg, Yael ^a   Porat, Rinnat ^a   Kedar, Inbal ^c   Shochat, Chen ^d   Galinsky, Daliah ^a   Hamburger, Tamar ^a   Hubert, Ayala ^a   Strul, Hana ^b   Kariiv, Revital ^b   Ben Avi, Liat ^a   Savion, Moran ^a   Pikarsky, Eli ^a   Abeliovich, Dvorah ^a   Bercovich, Dani ^d,e   Lerer, Israela ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TASMC   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^e TEL HAI COLLEGE   (Israel)

Author keywords

Ashkenazi; BRCA; Founder; HNPCC; MMR; MSH6

Indexed keywords

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER PATIENT; COLON CANCER; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC TRANSCRIPTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; STOMACH CANCER; URINARY TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR; ETHNIC GROUPS; FEMALE; GENE DELETION; GENES, BRCA2; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PEDIGREE;

EID: 77955052808     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-009-9298-9     Document Type: Article

References (25)

1. Abeliovich D, Kaduri L, Lerer I, Weinberg N et al (1997) The founder mutations 185delAG and 5382insc in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early onset breast cancer patients among Ashkenazi woman. Am J Hum Genet 60:505-514
2. Banjerjee SK, Maldisi WF, Weston AP et al (1995) Microwavebased DNA extraction from paraffin-embedded tissue for PCR amplification. BioTechniques 18:768-773
3. Chan TL, Wai Chan Y, Ho JW et al (2004) MSH2 c. 1452-1455de1AATG is a founder mutation and an important cause of Hereditary Nonpolyposis Colorectal Cancer in the southern Chinese population. Am J Hum Genet 74:1035-1042
4. Chen S et al (2006) Prediction of germline mutations and cancer risk in the lynch syndrome. JAMA 296:1479-1487
5. Foulkes W, Thiffault I, Gruber SB et al (2002) The founder mutation MSH2*1906G?C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 71(6):1395-1412
6. Fujita M et al (1995) Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer 64(6):361-366
7. Goldberg Y, Porat RM, Kedar I, Shochat C, Sagi M, Eilat A, Mendelson S, Hamburger T, Nissan A, Hubert A, Kadouri L, Pikarski E, Lerer I, Abeliovich D, Bercovich D, Peretz T (2008) Mutation spectrum in HNPCC in the Israeli population. Fam Cancer
8. Guillem JG, Glogowski E, Moore HG, Nafa K, Markowitz AJ, Shia J, Offit K, Ellis NA (2007) Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management. Ann Surg 245(4):560-565
9. Hegde M, Blazo M, Chong B, Prior T et al (2005) Assay validation for identification of hereditary nonpolyposis colon cancercausing mutations in mismatch repair genes MLH1, MSH2, and MSH6. J Mol Diagn 7(4):525-534
10. Hendriks YM, Wagner A, Morreau H et al (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127(1):17-25
11. Lynch HT, Coronel SM, Okimoto R et al (2004) A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA 291:718-724
12. Moisio AL, Sistonen P, Weissenbach J et al (1996) Age and origin of two common MLH1 mutations predisposing to hereditary colon cancer. Am J Hum Genet 59:1243-1251
13. Nilbert M, Wikman FP, Hansen TV, Krarup HB, Orntoft TF, Nielsen FC, Sunde L, Gerdes AM, Cruger D, Timshel S, Bisgaard ML, Bernstein I, Okkels H (2008) Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Fam Cancer
14. Nystrom-Lahti M, Kristo P, Nicolaides NC et al (1995) Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1:1203-1206
15. Peterlongo P et al (2003) MSH6 germline mutations are rare in colorectal cancer families. Int J Cancer 107(4):571-579
16. Rodriguez-Bigas MA, Boland CR et al (1997) A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758-1762
17. Shiri-Sverdlov R et al (2000) Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Hum Mutat 16(6):491-501
18. Sun S et al (2005) The HNPCC associated MSH2*1906G C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet 42:766-768
19. Thiffault I, Hamel N, Pal T, McVety S, Marcus VA, Farber D, Cowie S, Deschênes J, Meschino W, Odefrey F, Goldgar D, Graham T, Narod S, Watters AK, MacNamara E, Du Sart D, Chong G, Foulkes WD (2004) Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer 90(2):483-491
20. Toledano H, Goldberg Y, Kedar-Barnes I, Baris H, Porat RM, Shochat C, Bercovich D, Pikarsky E, Lerer I, Yaniv I, Abeliovich D, Peretz T (2008) Homozygosity of MSH2 c.1906G>[C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. Fam Cancer
21. Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268 (Pubitemid 38256271)
22. http://www.insight-group.org/mutations
23. http://genome.ucsc.edu: (GenBank Accession no. NM000249, NM000251, and NM000179 for MLH1, MSH2, and MSH6, respectively)
24. http://www.ncbi.nlm.nih.gov/SNP/) and the HGVbase (http://hgvbase.cgb.ki. se/)
25. http://primer3.sourceforge.net